PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer - Wikidata - awgldk - TriplyDB

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

http://www.wikidata.org/entity/Q34542434

about

Optimal management of hormone receptor positive metastatic breast cancer in 2016 Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.Breast cancer metastasis: issues for the personalization of its prevention and treatment.The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.Luminal breast cancer: from biology to treatment.Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.Precision medicine for metastatic breast cancer--limitations and solutions.Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients Targeting the mTOR pathway in breast cancer.Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.Genomic landscape of salivary gland tumors.A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.[Molecular classification of bladder cancer. Possible similarities to breast cancer].PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.Addressing the challenges of applying precision oncology.

P2860

Q26777683-9BB5B9E2-E08C-4734-A551-26649CCB16B9 Q28081872-3D591D58-92E8-41EE-8CF5-B4CAE4C9E513 Q33422744-5F3F17FD-0BBB-4853-9526-99FFBC94D637 Q33683126-F2ECA9B4-EDFD-4A00-B35E-0C9CC9570A94 Q33873653-622EC281-2DAE-4873-9AF4-63C5057AB213 Q33925164-D472DE9E-A0CB-424D-AE42-FB5596E7C4AD Q34486201-2D738317-883A-40A5-9978-A4224D868FA8 Q35053793-3504A7C1-CBAF-4927-98A3-60C841C47820 Q35446364-A18D1B21-337E-47DF-A0F6-255F60624B4F Q35833567-FECA5E7E-D37F-4207-9FA6-9E4682FC6083 Q35869498-05AE01AD-9D28-472C-95B7-2620C370F80B Q36141688-4AAE2D2B-C3D9-4E56-83DA-5DB6333FC8D5 Q36804506-ACDB9343-A8B0-4E02-9A34-6AD83CAAD77B Q37218214-80B189C4-5AC6-47D3-83AF-C59E949C7B40 Q37228078-A7A898F0-FE49-4182-861D-DB75437816B0 Q37254804-B01997D6-D314-40F5-A745-587B0A2C4076 Q37255106-5E99C21C-0C4F-41C9-8535-6F8D9EA9E329 Q37299288-7C9C6ADD-A5C3-41C4-82FB-9D46588E0045 Q37385372-B9DE33F3-8B1D-4789-B805-8A39B5EB1722 Q38110087-269D7262-CCF1-49E0-A1EF-5934F8AC57DF Q38123680-390B05D3-EADC-4199-A18E-7E35F2AED615 Q38346783-3C18C10E-E1FE-4E3A-9F53-DB76FCCCCA42 Q38551394-B9739B87-6A57-414F-8226-87B93D27BFE0 Q38925555-C88C014A-3901-472A-A002-D22D2483FDE3 Q39390640-A66B5BDB-CD73-47F8-9C3D-43841C738573 Q39920942-9269FD90-7E77-4888-A9F0-00327D039E1D Q41546576-FC222A3C-7515-4037-8F66-972B8E2BC636 Q41661081-6F6FA96A-AE5F-4A06-9109-261929340720 Q49544395-3FD1503C-D841-47E7-96E9-AA0C45FED9DE Q52334917-92E02CB7-EB17-44AD-81B2-BFD3EE554339 Q53205542-13A2F1D8-0C1E-4F66-9C81-70585F3FF9B2 Q54396852-FAA2EC01-A84C-4141-ADFC-20C32E2561DA Q55072067-4CE8F29D-B931-459A-965C-20B6A7980760 Q55314165-AD6A2E68-6CD0-4B71-A74B-B367ECB4A4BE

P2860

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

http://www.wikidata.org/entity/Q34542434

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@ast

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@en

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@nl

type

label

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@ast

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@en

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@nl

prefLabel

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@ast

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@en

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@nl

P1433

Q34542434-5CD277B1-4DAB-488B-A486-4BCD865DA318

P1476

Q34542434-D046711C-F6CD-446A-A983-378A5CA17AD9

P2093

Q34542434-00E3F3E6-E109-4C0E-B937-E1C2DBF9901A

Q34542434-23CBE21E-3CED-4473-BA9C-9AFCD1856A5C

Q34542434-3E5955E7-D643-49E8-8085-E691C8CE0394

Q34542434-8A1435B3-3C72-4A4A-B254-7EB261956FB0

Q34542434-C2729CB1-35AB-4611-B9EC-3AE6CC90A50F

Q34542434-DE1A67FC-89F5-4D1F-A827-16D68E50FC87

Q34542434-E8AA7165-315E-416D-A1FC-0E21656332D1

P2860

Q34542434-03F39CF6-8588-4BD3-88DE-72377AB8E9CA

Q34542434-1420F217-0A9A-4687-A1FA-7F0D55FC5592

Q34542434-1D65F63C-3B33-4AFF-B078-43B5EC912234

Q34542434-28C7B225-A954-4F6B-9B94-9798F81FFC1B

Q34542434-359B4AAD-9EE3-47E8-8A7E-9389E860AE9E

Q34542434-4CE78FED-8440-4B01-A9BD-65B74E775AE6

Q34542434-508A1F07-EF09-47D1-8318-327060318AED

Q34542434-7B21D901-8027-4079-8EE2-44DB6C7EE4D1

Q34542434-85E1CB3B-79EE-4616-B487-2F05BE7645C5

Q34542434-8C5764F3-4643-4B55-B9B5-89141900E19B

P304

Q34542434-E7321002-70CE-4DEA-B0DC-E9BE8ADF3D9D

P31

Q34542434-C904511D-8D75-461C-AD43-76807B65C393

P356

Q34542434-DEB3C223-683B-48A6-AE11-DCCAB68C320B

P407

Q34542434-5A726461-C658-4F38-A4D8-71EB226F8C42

P433

Q34542434-7093E7E2-7BA4-488F-92FE-8786DB2E8EBB

P478

Q34542434-7A65218E-A1AB-4939-99DC-92761D88CCDE

P50

Q34542434-0BF5EF5E-772F-44F3-BF57-40C23041C90F

Q34542434-32341353-684A-441F-B35F-34B2180AC7AA

Q34542434-85ADF2BF-9A59-4019-8A09-51FAC018D35D

Q34542434-93830638-9830-4D6A-9696-ECB31E0B63E3

P577

Q34542434-28B37D8A-8BBF-4C52-9565-9230DDD9D641

P5875

Q34542434-BF32B2B5-8A38-45F4-BBBC-7C1E22722B67

P698

Q34542434-B84B88F0-E763-4DC3-8E1A-1AA1F0BB9031

P921

Q34542434-48166445-9B4C-4DA2-9DEC-960C4075898B

P932

Q34542434-57B96FCD-EB6A-462C-AE5B-D133E6963807

P356

JOURNAL.PONE.0053292

P1433

P1476

PIK3CA genotype and a PIK3CA m ...... eceptor positive breast cancer

@en

P2093

Christos Sotiriou

http://www.w3.org/2001/XMLSchema#string

J Michael Dixon

http://www.w3.org/2001/XMLSchema#string

John M S Bartlett

http://www.w3.org/2001/XMLSchema#string

Martine J Piccart

http://www.w3.org/2001/XMLSchema#string

Sandeep K Singhal

http://www.w3.org/2001/XMLSchema#string

Tarek Sahmoud

http://www.w3.org/2001/XMLSchema#string

Vicky S Sabine

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

Exploiting the PI3K/AKT pathway for cancer drug discovery

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

P304

e53292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0053292

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Michiels

P577

2013-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234090657

http://www.w3.org/2001/XMLSchema#string

P698

23301057

http://www.w3.org/2001/XMLSchema#string

P921

estrogen-receptor positive breast cancer

P932

3534682

http://www.w3.org/2001/XMLSchema#string